Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30(suppl 5): F12–F23.
Nielsen A, Munk C, Kjaer SK. Trends in incidence of anal cancer and high-grade anal intraepithelial neoplasia in Denmark, 1978–2008. Int J Cancer 2012; 130: 1168–1173.
Nelson RA, Levine AM, Bernstein L, et al. Changing patterns of anal canal carcinoma in the United States. J Clin Oncol 2013; 31: 1569–1575.
Silverberg MJ, Lau B, Justice AC, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012; 54: 1026–1034.
Williams GR, Talbot IC. Anal carcinoma – a histological review. Histopathology 1994; 25: 507–516.
Abramowitz L, Jacquard AC, Jaroud F, et al. Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study. Int J Cancer 2011; 129: 433–439.
De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009; 124: 1626–1636.
Baricevic I, He X, Chakrabarty B, et al. High-sensitivity human papilloma virus genotyping reveals near universal positivity in anal squamous cell carcinoma: different implications for vaccine prevention and prognosis. Eur J Cancer 2015; 51: 776–785.
Meulendijks D, Tomasoa NB, Dewit L, et al. HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53. Br J Cancer 2015; 112: 1358–1366.
Serup-Hansen E, Linnemann D, Skovrider-Ruminski W, et al. Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal. J Clin Oncol 2014; 32: 1812–1817.
Valmary-Degano S, Jacquin E, Pretet JL, et al. Signature patterns of human papillomavirus type 16 in invasive anal carcinoma. Hum Pathol 2013; 44: 992–1002.
Stanley MA, Winder DM, Sterling JC, et al. HPV infection, anal intra-epithelial neoplasia (AIN) and anal cancer: current issues. BMC Cancer 2012; 12: 398.
Winburn GB. Anal carcinoma or ‘just hemorrhoids’? Am Surg 2001; 67: 1048–1058.
Osborne MC, Maykel J, Johnson EK, et al. Anal squamous cell carcinoma: an evolution in disease and management. World J Gastroenterol 2014; 20: 13052–13059.
Yang EJ, Quick MC, Hanamornroongruang S, et al. Microanatomy of the cervical and anorectal squamocolumnar junctions: a proposed model for anatomical differences in HPV-related cancer risk. Mod Pathol 2015; 28: 994–1000.
Das P, Crane CH, Eng C, et al. Prognostic factors for squamous cell cancer of the anal canal. Gastrointest Cancer Res 2008; 2: 10–14.
Lampejo T, Kavanagh D, Clark J, et al. Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review. Br J Cancer 2010; 103: 1858–1869.
Myklebust MP, Fluge O, Immervoll H, et al. Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients. Br J Cancer 2012; 106: 756–762.
Longuespee R, Alberts D, Pottier C, et al. A laser microdissection-based workflow for FFPE tissue microproteomics: important considerations for small sample processing. Methods 2016; 104: 154–162.
Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nature Biotechnol 2008; 26: 1367–1372.
Vizcaino JA, Deutsch EW, Wang R, et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nature Biotechnol 2014; 32: 223–226.
Vizcaino JA, Csordas A, del-Toro N, et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res 2016; 44: D447-D456.
Herfs M, Parra-Herran C, Howitt BE, et al. Cervical squamocolumnar junction-specific markers define distinct, clinically relevant subsets of low-grade squamous intraepithelial lesions. Am J Surg Pathol 2013; 37: 1311–1318.
Hubert P, Herman L, Roncarati P, et al. Altered alpha-defensin 5 expression in cervical squamocolumnar junction: implication in the formation of a viral/tumour-permissive microenvironment. J Pathol 2014; 234: 464–477.
Mirkovic J, Howitt BE, Roncarati P, et al. Carcinogenic HPV infection in the cervical squamo-columnar junction. J Pathol 2015; 236: 265–271.
Herfs M, Vargas SO, Yamamoto Y, et al. A novel blueprint for ‘top down’ differentiation defines the cervical squamocolumnar junction during development, reproductive life, and neoplasia. J Pathol 2013; 229: 460–468.
Kocjan BJ, Seme K, Poljak M. Comparison of the Abbott RealTime High Risk HPV test and INNO-LiPA HPV Genotyping Extra test for the detection of human papillomaviruses in formalin-fixed, paraffin-embedded cervical cancer specimens. J Virol Methods 2011; 175: 117–119.
Patel V, Hood BL, Molinolo AA, et al. Proteomic analysis of laser-captured paraffin-embedded tissues: a molecular portrait of head and neck cancer progression. Clin Cancer Res 2008; 14: 1002–1014.
Steiner C, Ducret A, Tille JC, et al. Applications of mass spectrometry for quantitative protein analysis in formalin-fixed paraffin-embedded tissues. Proteomics 2014; 14: 441–451.
Braakman RB, Tilanus-Linthorst MM, Liu NQ, et al. Optimized nLC-MS workflow for laser capture microdissected breast cancer tissue. J Proteomics 2012; 75: 2844–2854.
Finne K, Vethe H, Skogstrand T, et al. Proteomic analysis of formalin-fixed paraffin-embedded glomeruli suggests depletion of glomerular filtration barrier proteins in two-kidney, one-clip hypertensive rats. Nephrol Dial Transplant 2014; 29: 2217–2227.
Liu NQ, Braakman RB, Stingl C, et al. Proteomics pipeline for biomarker discovery of laser capture microdissected breast cancer tissue. J Mammary Gland Biol Neoplasia 2012; 17: 155–164.
Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial–mesenchymal transition. Nature Rev Mol Cell Biol 2014; 15: 178–196.
Karantza V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene 2011; 30: 127–138.
Wang X, Ouyang H, Yamamoto Y, et al. Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell 2011; 145: 1023–1035.
Herfs M, Yamamoto Y, Laury A, et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A 2012; 109: 10516–10521.
Wang H, Sun R, Lin H, et al. P16INK4A as a surrogate biomarker for human papillomavirus-associated oropharyngeal carcinoma: consideration of some aspects. Cancer Sci 2013; 104: 1553–1559.
Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24–35.
Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333: 1157–1160.
Hanns E, Job S, Coliat P, et al. Human papillomavirus-related tumours of the oropharynx display a lower tumour hypoxia signature. Oral Oncol 2015; 51: 848–856.
Maruyama H, Yasui T, Ishikawa-Fujiwara T, et al. Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population. Cancer Sci 2014; 105: 409–417.
Williams GR, Talbot IC, Leigh IM. Keratin expression in anal carcinoma: an immunohistochemical study. Histopathology 1997; 30: 443–450.
Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist 2004; 9: 606–616.
D'Amico AV, Whittington R, Malkowicz SB, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999; 17: 168–172.
Barletta JA, Yeap BY, Chirieac LR. Prognostic significance of grading in lung adenocarcinoma. Cancer 2010; 116: 659–669.
Moro-Sibilot D, Lantuejoul S, Diab S, et al. Lung carcinomas with a basaloid pattern: a study of 90 cases focusing on their poor prognosis. Eur Respir J 2008; 31: 854–859.
Soriano E, Faure C, Lantuejoul S, et al. Course and prognosis of basaloid squamous cell carcinoma of the head and neck: a case–control study of 62 patients. Eur J Cancer 2008; 44: 244–250.
Das P, Bhatia S, Eng C, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys 2007; 68: 794–800.
Kwok HF, Zhang SD, McCrudden CM, et al. Prognostic significance of minichromosome maintenance proteins in breast cancer. Am J Cancer Res 2015; 5: 52–71.
Hua C, Zhao G, Li Y, et al. Minichromosome maintenance (MCM) family as potential diagnostic and prognostic tumour markers for human gliomas. BMC Cancer 2014; 14: 526.
Gakiopoulou H, Korkolopoulou P, Levidou G, et al. Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications. Br J Cancer 2007; 97: 1124–1134.
Scarpini C, White V, Muralidhar B, et al. Improved screening for anal neoplasia by immunocytochemical detection of minichromosome maintenance proteins. Cancer Epidemiol Biomarkers Prev 2008; 17: 2855–2864.
Drissi R, Dubois ML, Douziech M, et al. Quantitative proteomics reveals dynamic interactions of the minichromosome maintenance complex (MCM) in the cellular response to etoposide induced DNA damage. Mol Cell Proteomics 2015; 14: 2002–2013.
